<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933319</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DMS-BC-11</org_study_id>
    <nct_id>NCT03933319</nct_id>
  </id_info>
  <brief_title>Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer</brief_title>
  <official_title>Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center phase Ⅱ study designed to evaluated the efficacy and safety of
      pegylated liposomal doxorubicin（PLD）in combination with trastuzumab in HER-2 positive
      metastatic breast cancer .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>The ORR will be calculated as the proportion of patients in the Efficacy Evaluable Patient Set who achieve complete response (CR) and partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approximately 1.5 years</time_frame>
    <description>PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of adverse events</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PLD in combination with trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab: administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
pegylated liposomal doxorubicin(PLD):administered at dose of 35mg/m2 IV once every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin</intervention_name>
    <description>Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity</description>
    <arm_group_label>PLD in combination with trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and voluntarily receive the research procedures according to
             protocol,willingness to sign the written informed consent document;

          -  Female patients aged from 18 to 70 years old；

          -  Histologically confirmed as invasive breast cancer；

          -  HER-2 Positive（defined by: IHC 3+ or ISH positive）, regardless of HR status;

          -  Recurrence after adjuvant therapy or metastatic breast cancer，and chemotherapy naïve
             in the metastatic setting or had one prior regimen for metastatic breast cancer；

          -  Patients must have measurable disease according to RECIST criteria Version 1.1（Brain
             metastases lesions and bone metastases lesions were excluded）;

          -  The adverse event caused by prior therapy has recovered, or stabilized, or does not
             affect the study administration according to the investigator's judgment；

          -  Performance status 0-1；

          -  Life expectancy of at least 3 months；

          -  Left ventricular ejection fraction (LVEF)≥55%；

          -  Brain natriuretic peptide (BNP) and cardiac troponin T (cTnT) were in the normal
             range；

          -  Patients must have normal ECG；

          -  Bone marrow function: absolute neutrophil count
             (ANC)≥1.5×109/L，platelets≥100×109/L，hemoglobin ≥90g/L；

          -  Hepatic function：alanine aminotransferase(ALT) and aspartate aminotransferase(AST)
             ≤2.5×ULN，serum total bilirubin≤ 1.5×ULN，or ≤2.5×ULN who has Gilbert's syndrome;

          -  Renal function：serum creatinine≤1.5×ULN；

          -  Coagulation function：the international standardized ratio (INR) ≤1.5×ULN, prothrombin
             time (PT) or the activated partial thrombin time (APTT) ≤1.5×ULN.

        Exclusion Criteria:

          -  Patients with symptomatic brain metastases.

          -  Patients who are known or suspected to be allergic to the active ingredient or
             excipients of the investigational drug.

          -  Prior cumulative dose of 240 mg/m2 for doxorubicin and 400 mg/m2 for epirubicin.

          -  Prior treatment with anthracyclines has caused cardiotoxicity, or failed (disease
             progression during therapy or recurrence and metastasis within 12 months after
             adjuvant therapy).

          -  Prior mediastinal radiotherapy.

          -  Participation in other clinical trials within 4 weeks before enrollment.

          -  Severe cardiovascular disease, including history of congestive heart failure, acute
             myocardial infarction within 6 months before enrollment, transmural myocardial
             infarction measured by ECG, uncontrolled arrhythmia, angina requiring therapy,
             clinically significant valvular heart disease, uncontrolled hypertension.

          -  Severe or uncontrolled infection.

          -  Positivity for HIV, Hepatitis B or C.

          -  Active malignancy in the past 5 years (other than carcinoma in situ of the cervix or
             basal cell carcinoma of the skin).

          -  Patients who are pregnant , breastfeeding ,or refuse to use adequate contraception
             during the course of participation.

          -  Need to concurrent other cancer therapy(other than palliative care for non-target
             lesions).

          -  Other ineligible conditions according to the researcher's judgment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>peng yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>peng yuan, Prof</last_name>
    <phone>13501270834</phone>
    <phone_ext>13501270834</phone_ext>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peng Yuan</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>peng yuan, Prof</last_name>
      <phone>13501270834</phone>
      <phone_ext>13501270834</phone_ext>
      <email>yuanpeng01@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>xue wang, Dr</last_name>
      <phone>13811967690</phone>
      <phone_ext>13501270834</phone_ext>
      <email>wxyxuki@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Peng Yuan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

